AddaxBiosciences

Addax Biosciences is an Italian company that develops innovative histological fixatives to replace toxic formaldehyde in healthcare and research settings. The headquarters location is not specified on the website.

Here are key aspects of the company:

• Innovation: The company developed GAF, a non-carcinogenic histological fixative designed as a direct substitute for Formalin to protect workers from occupational health risks.
• Collaborations: Addax Biosciences partners with major institutions including the University of Turin, A.O.U. Città della Salute e della Scienza in Turin, and the Candiolo Cancer Institute – IRCCS for research and clinical validation projects.
• Funding: The organization has secured significant support from the European Union’s Horizon 2020 Research and Innovation Programme and the Piedmont Regional Program to consolidate its innovative start-up initiatives.

Addax Biosciences addresses a critical gap in healthcare safety by providing a technically viable solution that balances diagnostic needs with the imperative of worker protection against carcinogenic exposure.